Prediction of radiological outcome in early rheumatoid arthritis in clinical practice:: role of antibodies to citrullinated peptides (anti-CCP)

被引:351
作者
Forslind, K
Ahlmén, M
Eberhardt, K
Hafström, I
Svensson, B
机构
[1] Helsingborgs Lasarett, Rheumatol Sect, Helsingborg, Sweden
[2] Sahlgrenska Univ Hosp, Dept Rheumatol, Molndal, Sweden
[3] Univ Lund Hosp, Dept Rheumatol, S-22185 Lund, Sweden
[4] Huddinge Univ Hosp, Karolinska Inst, Dept Rheumatol, Stockholm, Sweden
关键词
D O I
10.1136/ard.2003.014233
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To investigate the role of anti-cyclic citrullinated peptide antibody (anti-CCP) for the prediction of radiological outcome in patients with early rheumatoid arthritis. Methods: Anti-CCP was assessed at baseline in 379 patients with early rheumatoid arthritis ( disease duration <1 year). Radiological joint damage and progression were assessed by Larsen score after two years of follow up (end point) and used as outcome variables. The prognostic value of anti-CCP and other demographic and disease related baseline variables were assessed by univariate and multivariate analyses, including calculation of odds ratios (OR), predictive values, and multiple logistic regression models. Results: The presence of anti-CCP was associated with significantly higher Larsen score both at baseline and at end point. Univariate predictor analysis showed that anti-CCP had the highest significant OR for radiological joint damage and progression after baseline Larsen score, followed by rheumatoid factor, erythrocyte sedimentation rate (ESR), C reactive protein, age, smoking status, and sex. In stepwise multiple regression analyses, baseline Larsen score, anti-CCP, and ESR were selected as significant independent predictors of the radiological outcomes. Conclusions: There is good evidence for an association of anti-CCP with radiological joint changes in rheumatoid arthritis. Anti-CCP is an independent predictor of radiological damage and progression. Though prediction in early rheumatoid arthritis is still far from perfect, the use of anti-CCP in clinical practice should make it easier for rheumatologists to reach judicious treatment decisions.
引用
收藏
页码:1090 / 1095
页数:6
相关论文
共 36 条
[1]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[2]  
Combe B, 2001, ARTHRITIS RHEUM, V44, P1736, DOI 10.1002/1529-0131(200108)44:8<1736::AID-ART308>3.0.CO
[3]  
2-I
[4]   Associations of HLA-DRB and -DQB genes with two and five year outcome in rheumatoid arthritis [J].
Eberhardt, K ;
Fex, E ;
Johnson, U ;
Wollheim, FA .
ANNALS OF THE RHEUMATIC DISEASES, 1996, 55 (01) :34-39
[5]   ASSESSING DISABILITY IN PATIENTS WITH RHEUMATOID-ARTHRITIS - USE OF A SWEDISH VERSION OF THE STANFORD HEALTH ASSESSMENT QUESTIONNAIRE [J].
EKDAHL, C ;
EBERHARDT, K ;
ANDERSSON, SI ;
SVENSSON, B .
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1988, 17 (04) :263-271
[6]  
Forslind K, 2000, SCAND J RHEUMATOL, V29, P320
[7]  
Forslind K, 2001, SCAND J RHEUMATOL, V30, P221
[8]   An eight year prospective study of outcome prediction by antiperinuclear factor and antikeratin antibodies at onset of rheumatoid arthritis [J].
Genevay, S ;
Hayem, G ;
Verpillat, P ;
Meyer, O .
ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (08) :734-736
[9]   Early inflammatory polyarthritis: results from the Norfolk Arthritis Register with a review of the literature. II. Outcome at three years [J].
Harrison, B ;
Symmons, D .
RHEUMATOLOGY, 2000, 39 (09) :939-949
[10]   Influence of cigarette smoking on disease outcome in rheumatoid arthritis [J].
Harrison, BJ .
CURRENT OPINION IN RHEUMATOLOGY, 2002, 14 (02) :93-97